Comparison of the induction of neutralizing antibodies against Bas congo virus using several vaccine modalities

The Bas-Congo virus (BASV) is a novel rhabdovirus that causes viral hemorrhagic fever in 2009. Since BASV has not been isolated, there is limited information on BASV, and potential therapeutics or vaccines have not yet been developed. In the present study, we used the synthetic cDNA of the BASV-G protein to develop 4 different types of vaccine, using a recombinant BASV-G protein, a plasmid DNA that expresses the BASV-G protein, a recombinant vaccinia virus that expresses the BASV-G protein, and a pseudotype virus based on hydrogen peroxide-inactivated vesicular stomatitis virus (VSV) that expresses the BASV-G protein (BASVpv). BASVpv was generated and used for the evaluation of neutralizing antibodies and the induction of virus neutralizing antibody upon inoculation (BASVpv/GFP) of these candidates in rabbits. The results showed that both the recombinant vaccinia virus and the hydrogen peroxide-inactivated VLPs effectively induced neutralizing antibodies, even with a single inoculation.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2025-05-10
DOI
https://doi.org/10.1038/s41598-025-01213-w
Primary Topic
Plant Virus Research Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparison of the induction of neutralizing antibodies against Bas congo virus using several vaccine modalities

Hideki Tani, Koichi Imaoka, Tomoki Yoshikawa, Shigeru Morikawa et al.
Scientific Reports
Plant Virus Research Studies
article

Comparison of the induction of neutralizing antibodies against Bas congo virus using several vaccine modalities

Hideki Tani, Koichi Imaoka, Tomoki Yoshikawa, Shigeru Morikawa, Ken Maeda, Masayuki Saijo, Masanobu Kimura, Eun‐Sil Park, Yoshihiro Kaku
article en

Abstract

The Bas-Congo virus (BASV) is a novel rhabdovirus that causes viral hemorrhagic fever in 2009. Since BASV has not been isolated, there is limited information on BASV, and potential therapeutics or vaccines have not yet been developed. In the present study, we used the synthetic cDNA of the BASV-G protein to develop 4 different types of vaccine, using a recombinant BASV-G protein, a plasmid DNA that expresses the BASV-G protein, a recombinant vaccinia virus that expresses the BASV-G protein, and a pseudotype virus based on hydrogen peroxide-inactivated vesicular stomatitis virus (VSV) that expresses the BASV-G protein (BASVpv). BASVpv was generated and used for the evaluation of neutralizing antibodies and the induction of virus neutralizing antibody upon inoculation (BASVpv/GFP) of these candidates in rabbits. The results showed that both the recombinant vaccinia virus and the hydrogen peroxide-inactivated VLPs effectively induced neutralizing antibodies, even with a single inoculation.

Scientific ReportsVol. 15(1)
Okayama University of Science (JP), National Institute of Infectious Diseases (JP), Toyama Institute of Health (JP)
Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science
Openalex Percentile: Top 93%
Plant Virus Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.